Copyright
©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1258-1167
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1258
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1258
Table 1 Baseline characteristics of the study population
| Characteristic | Males | Females | Total |
| Sex | 8 | 21 | 29 |
| Race | |||
| Caucasian | 7 | 16 | 23 |
| African American | 1 | 4 | 5 |
| Other/unknown | 0 | 1 | 1 |
| Presence of | |||
| Diabetes | 3 | 15 | 18 |
| Hypertension | 8 | 17 | 25 |
| Obesity | 5 | 10 | 15 |
| Reason for PCSK-9 inhibitor initiation | |||
| Statin intolerance | 4 | 16 | 20 |
| Inadequate lipid control | 2 | 4 | 6 |
| Not known | 2 | 1 | 3 |
- Citation: Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167
- URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1258